Recombinant Human Cytochrome P450 2A6 (CYP2A6) Protein (His&Myc)

Name: Recombinant Human Cytochrome P450 2A6 (CYP2A6) Protein (His&Myc)
Brand: Beta LifeScience
SKU: BLC-04873P
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Cytochrome P450 2A6 (CYP2A6) Protein (His&Myc) is produced by our E.coli expression system. This is a protein fragment.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	P11509
Target Symbol	CYP2A6
Synonyms	Coumarin 7 hydroxylase; Coumarin 7-hydroxylase; CP2A6_HUMAN; CPA6; CYP2A; CYP2A3; CYP2A6; CYPIIA6; Cytochrome P450 2A6; Cytochrome P450 IIA3; Cytochrome P450 subfamily IIA (phenobarbital inducible) polypeptide 6; Cytochrome P450(I); Cytochrome P450; family 2 subfamily A polypeptide 6; Flavoprotein linked monooxygenase; P450C2A; P450PB; Xenobiotic monooxygenase
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-10His&C-Myc
Target Protein Sequence	SKGKLPPGPTPLPFIGNYLQLNTEQMYNSLMKISERYGPVFTIHLGPRRVVVLCGHDAVREALVDQAEEFSGRGEQATFDWVFKGYGVVFSNGERAKQLRRFSIATLRDFGVGKRGIEERIQEEAGFLIDALRGTGGANIDPTFFLSRTVSNVISSIVFGDRFDYKDKEFLSLLRMMLGIFQFTSTSTGQLYEMFSSVMKHLPGPQQQAFQLLQGLEDFIAKKVEHNQRTLDPNSPRDFIDSFLIRMQEEEKNPNTEFYLKNLVMTTLNLFIGGTETVSTTLRYGFLLLMKHPEVEAKVHEEIDRVIGKNRQPKFEDRAKMPYMEAVIHEIQRFGDVIPMSLARRVKKDTKFRDFFLPKGTEVFPMLGSVLRDPSFFSNPQDFNPQHFLNEKGQFKKSDAFVPFSIGKRNCFGEGLARMELFLFFTTVMQNFRLKSSQSPKDIDVSPKHVGFATIPRNYTMSFLPR
Expression Range	29-494aa
Protein Length	Partial
Mol. Weight	60.8 kDa
Research Area	Cardiovascular
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Subcellular Location	Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein.
Protein Families	Cytochrome P450 family
Database References	HGNC: 2610 OMIM: 122720 KEGG: hsa:1548 STRING: 9606.ENSP00000301141 UniGene: PMID: 28432340 genetic association studies in population in China: Data suggest that SNPs in CYP2C9 and CYP2A6 are associated with hepatotoxicity due to antiepileptic drug valproate in the population studied. (CYP2C9 = cytochrome P450 family 2 subfamily C member 9; CYP2A6 = cytochrome P450 family 2 subfamily A member 6) PMID: 28273397 Our results demonstrated the presence of functional variability in CYP2a6 activities resulting from amino acid substitutions caused by genetic polymorphisms. PMID: 27974382 Cynomolgus monkey CYP2A24, which shows 95% amino acid identity to human CYP2A6. PMID: 27625140 CYP2A6 rs60823196 and rs138978736 are possible risk factors for serious toxicity in Chinese gastric carcinoma patients treated with S-1 plus oxaliplatin chemotherapy. PMID: 28811232 Genetic polymorphisms in CYP2B6 and CYP2A6 explained a significant proportion of variability in EFV plasma concentration in HIV-infected children in a multi-ethnic outpatient clinic. PMID: 28886044 In a Mexican Mestizo population, rs1137115(A) and rs4105144(T) in CYP2A6 are associated with cigarette consumption PMID: 28734893 CYP2B6/CYP2A6 genotypes were associated with increased reported suicidality among AIDS patients who had been randomly assigned to receive efavirenz-containing regimens in clinical trials. Strength of association varied by race/ethnicity. PMID: 28931220 The CYP2A6 gene product plays a major role in the nicotine metabolism pathway, which influences nicotine intake. PMID: 27113016 CYP2A6 activity provides information on lung cancer risk that is not captured by smoking history. PMID: 28542511 CYP2A64 genetic polymorphisms may not strongly affect smoking behavior but may possibly have an effect on nicotine dependence PMID: 26370685 CYP2A6 genetic variation alters striatal-cingulate circuits, network hubs, and executive processing in smokers. Because the CYP2A6 effect was seen only in smokers, these data suggest that the rate of nicotine metabolism-and thus the concentration of nicotine presented to the brain over the course of nicotine addiction-shapes brain circuits that, among other functions, compute reward and impulsivity processes. PMID: 27865452 a greater CYP2A6 activity causes smokers to smoke more extensively and be exposed to higher levels of carcinogens, resulting in an increased risk for lung cancer. PMID: 27488534 Gene Amplification and Potential Overexpression of Cyp2a5/CYP2A6 Are Associated with the Invasive Phenotype PMID: 27902773 study demonstrated a strong dose-dependent association between reduced CYP2A6 activity determined by genotypes and reduced risk of lung cancer PMID: 28182203 Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank PMID: 27815364 drug and the major metabolites were compared with the kinsenoside-cotreated samples. The effect of kinsenoside was negligible on the enzyme activity of all the CYP isozymes tested even though CYP2A6 was slightly inhibited at higher concentrations. PMID: 27322236 CYP2A6 gene variants were associated with markedly reduced nicotine and cotinine clearances. PMID: 27035242 CYP2A6 polymorphisms are associated with poor response to chemotherapy in gastric cancer. PMID: 26715117 Combined 3D-QSAR and docking procedures yielded precise information about the common and distinct interactions of inhibitors and the enzyme active sites of CYP2A6. PMID: 26648056 P450 2A13 is one of the important enzymes that oxidizes polycyclic aromatic hydrocarbons PMID: 26247835 It was concluded that, although decreased CYP2A6 AS tended to reduce the risk of bladder cancer in Japanese smokers, no significant association was recognized in this population. PMID: 26725431 Reduced metabolism CYP2A6 genotypes are associated with both risk and protective effects in young smokers. PMID: 25744963 Slow nicotine metabolism mediated by CYP2A6 increases risk for tobacco dependence throughout adolescence. PMID: 26644138 carcinogen exposure and thereby lower risk of lung cancer. Despite the association between nicotine metabolism (CYP2A6 activity phenotype and diplotypes) and smoking intensity PMID: 26818358 lower lung cancer risk observed in CYP2A6 poor metabolizers is partially explained by the strong influence of CYP2A6 genetic polymorphisms on nicotine uptake and metabolism PMID: 26662855 phenotypic association studies in population in Nigeria: Data suggest polymorphisms in CYP2A6 exist in the population studied; distribution of CYP2A6 activity is trimodal; influence of age/sex on activity are not significant in this biomarker study. PMID: 26098700 No associations were found between the analyzed variants and smoking, however, there was an association among non-smoking subjects between the A allele of rs16969968 and high body mass index. PMID: 26757861 Report isolation of CYP2A6 inhibitors from Vernonia cinerea. PMID: 25857233 Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes. PMID: 26366873 CYP2A6 genetic polymorphisms may play important roles in the development of SQCC in Japanese smokers. PMID: 26091970 The detected CYP2A6 variants explain a strikingly large fraction of variance (up to 31%) in nicotine metabolite ratio (NMR) in these study samples. PMID: 26407342 differences in genetic variations and haplotypes of CYP2A6, CYP2B6, CYP2C8, and CYP2E1 were observed among ethnic populations. PMID: 24988984 We have for the first time demonstrated that the tumor suppressor protein, p53, is a regulator of the CYP2A6 gene. PMID: 26343999 CYP2A7 affects CYP2A6 expression by competing for miR-126 binding. PMID: 25710939 meta-analysis suggests that CYP2A6 gene polymorphism is associated with daily cigarette consumption. No association with tobacco dependence was found. PMID: 25683822 Nicotine dependence among current smokers homozygous for the SLC6A3 10r allele was lower than that of smokers carrying minor alleles, a CYP2A6 polymorphism might mediate this association. PMID: 25526961 Genetic variation in CYP2A6 protein influence smoking behaviors to carbon monoxide level. PMID: 25072098 The effects of Smilax root on reactive oxygen species and CYP2A6 expression in Hep G2 cells are reported. PMID: 25220663 Nicotine replacement therapy is effective among individuals with fast, but not slow, CYP2A6-defined nicotine metabolism. The effect of bupropion on relapse likelihood is unlikely to be affected by nicotine metabolism as estimated from CYP2A6 genotype. PMID: 24033696 secondhand smoke-exposed pregnant women with CYP2A61/4 or 4/4 genotype had a significantly lower median cotinine level than women with CYP2A61/1 genotype PMID: 24163286 Polymorphisms in CYP2A6 gene is associated with Crohn's disease. PMID: 24651583 CYP2A6 is located within genes previously associated with chronic obstructive pulmonary disease susceptibility in smokers. PMID: 25006744 Genetic variations in CYP2A6 gene or genotypes associated with reduced synaptic serotonin activity may influence the success of smoking cessation treatment. PMID: 24127329 Results show that variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk. PMID: 24045616 study identified seven novel nonsynonymous variants in a population of African American light smokers; each reduced in-vitro CYP2A6 protein expression, enzymatic activity and/or stability, consistent with the associated slow metabolism phenotype. PMID: 24305170 CYP2A6 activity was higher in Swedes compared to Koreans (p<0.0001), even among carriers of rapid genotypes. We report major differences in CYP2A6 enzyme activity between Swedes and Koreans mainly due to CYP2A6 genetic variation but not exclusively. PMID: 22850738 CYP2A6 and UGT2B10 genotype explain 53% of the variance in oral nicotine glucuronidation. They are also significantly associated with undeuterated (D0) nicotine glucuronidation in individuals smoking ad libitum. PMID: 24192532 Selective chemical inhibitors of CYP2A6 inhibited metronidazole 2-hydroxylation. PMID: 23813797 The presence of the CYP2A6 1/1 deletion polymorphism might be associated with an increased lung cancer risk, especially for Asians. PMID: 23733493

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.